Investigation of the Anticancer and Proliferative Effect of Broccoli Extract on Du145 Prostate Cancer and MEF Healthy Fibroblast Cell Lines

In recent years, many researchers have focused on the health effects of plant-derived foods. In this context, foods with high content of flavonoids and phenolic substances have received a great deal of attention as potential agents for cancer prevention and treatment. Studies on the broccoli plant have revealed that broccoli has antioxidant and anti-carcinogenic properties. However, effective dose of broccoli needs to be determined for the cancer treatment. In this study, the effects of broccoli extracts on du145 prostate cancer and Mef fibroblast healthy cells were investigated at different doses for 48 hours. Du145 and Mef cells were grown with Dulbecco%252339%253Bs Minimum Essential Medium (DMEM) and HAMS F 12 (1%253A 1) supplemented with 2%25 FBS. Broccoli extracts at ten different doses (0,19%25 - 100%25) were added into cultures and incubated at 37deg%253BC for 24 and 48 h in 5%25 CO2. The viability of the cells was determined by the MTT method (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide). Probit analysis by SPSS software revealed that the broccoli extract at a dose of 4.070 %25 dose killed du145 cancer cells at 48 h. At the same time, MTT results showed that the viability of Mef cells was increased during 48 h of incubation. As a result, broccoli extract showed a significant level of anticancer activity in Du145 cells, while increasing the viability of Mef healthy cells. This result suggests that broccoli extract is a potential candidate for cancer treatment

Clinical and Histopathologic Differential Diagnosis of Venous Malformation of the Uterine Cervix

Ustuner, Isik/0000-0002-3791-4071; GUCER, HASAN/0000-0002-9122-379XWOS: 000330369100006PubMed: 23609595Objective. Venous malformations of the uterine cervix are extremely rare. Most lesions are asymptomatic and incidental, but sometimes, they may present with abnormal and/or intractable vaginal bleeding. the study aimed to describe a case of venous malformation of the uterine cervix and discuss the clinical and histopathologic differential diagnosis of this entity. Case. A 50-year-old woman attended to the gynecology clinic for postcoital spotting and postmenopausal bleeding. Gynecologic examination revealed polypoid, lobulated, bluish, vascular nodular lesions 4 to 1 cm in size surrounding the cervical introitus. the lesions were completely excised via loop electrosurgical excision procedure method. Pathologic diagnosis revealed venous malformations of the uterine cervix. Conclusions. Venous malformations of the uterine cervix should be considered in the differential diagnosis of patients with cervical mass and vaginal bleeding. Pathologic examination is necessary in such a case to exclude the possibility ofmalignant vascular tumor or cervical neoplasm

The Value of HBME-1 and Claudin-1 Expression Profile in the Distinction of BRAF-Like and RAS-Like Phenotypes in Papillary Thyroid Carcinoma

GUCER, HASAN/0000-0002-9122-379X; Mete, Ozgur/0000-0003-0469-2801WOS: 000381594800007PubMed: 27153840This study compared the expression profile of HBME-1 and claudin-1 in 90 papillary thyroid carcinomas (PTCs) with respect to the tumor architecture and invasive growth as reflected in 46 BRAF-like, 31 non-invasive RAS, and 13 invasive RAS-like phenotypes. Individual tumors were given an expression score (max 300) by multiplying the percent positive tumor cells by the intensity score (range 0-3). the higher expression of HBME-1 and claudin-1 distinguished BRAF-like phenotype from RAS-like phenotype. the same correlation was also retained for both markers when comparing BRAF-like phenotype with non-invasive and invasive RAS-like phenotypes. the expression scores and positivity rates for both markers did not yield any statistical difference among BRAF-like PTCs. Except the higher positivity rate of HBME-1, invasive RAS-like tumors were not statistically different than their non-invasive counterparts with respect to the positivity rate of claudin-1 and the expression scores of both markers. A central lymph node dissection or selective lymph node sampling was available in 20 specimens. the absence of claudin-1 expression has not been a feature of lymph node metastasis in this series. Despite the limited number of nodal sampling, BRAF-like phenotype and claudin-1 positivity status have been considered the best determinants of positive predictive value and negative predictive value in the prediction of lymph node metastasis among variables, respectively. Adoption of the simplified architectural classification approach to PTCs showed distinct biomarker expression profile in this series; however, immunohistochemistry for HBME-1 and claudin-1 does not seem to be useful in the distinction of invasive RAS-like PTCs from their non-invasive counterparts. Given the overlapping molecular signatures within the RAS-like phenotype, further studies with additional biomarkers are still needed to identify distinct protein expression signatures of non-invasive RAS-like phenotype as this diagnostic category still remains a surgical diagnosis at this time.Recep Tayyip Erdogan University Scientific Research Support FundThis study has received financial support from Recep Tayyip Erdogan University Scientific Research Support Fund